GlassScriptPhysician profile
Morgan B Mcgee
NPI 1821863036
$944.58
in general payments reported to CMS, 2019-2025
22 companies · $607 in 2025
The $607 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $338 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201.62 | 2024-2025 | |
| Axsome Therapeutics, INC. | $75.24 | 2025 | Auvelity |
| Novo Nordisk INC | $69.70 | 2025 | Wegovy |
| Biogen, INC. | $56.92 | 2024 | Skyclarys, Vumerity |
| Dexcom, INC. | $50.05 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $48.14 | 2024-2025 | Vyepti, Rexulti |
| Ani Pharmaceuticals, INC. | $47.10 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $38.16 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $37.56 | 2024 | Austedo Xr |
| Pfizer INC. | $37.42 | 2024-2025 | |
| Antares Pharma, INC. | $36.93 | 2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.26 | 2025 | Xifaxan |
| Lilly USA, LLC | $29.42 | 2025 | Kisunla, Zepbound, Mounjaro |
| Ucb, INC. | $28.50 | 2024 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $25.40 | 2024 | Ultomiris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $24.84 | 2024 | Brixadi |
| Astellas Pharma US INC | $20.17 | 2025 | Veozah |
| Tanabe Pharma America, INC. | $18.52 | 2024 | |
| Abbott Laboratories | $16.91 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.81 | 2025 | Caplyta |
| Boston Scientific Corporation | $16.67 | 2024 | |
| Currax Pharmaceuticals LLC | $14.24 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.